Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (905)	3/31/2000 2:37:00 PM
From: tuck	Respond to of 52153

Peter, NEXL is one of the companies that Paramount/Aries is involved with, I believe via converts. The reverse split thickens the plot some. Particularly because I have a shred of evidence that they just bailed out of ENZN a few weeks ago (link supplied by PM upon demonstration of interest). Could they be bailing here, too? Cheers, Tuck

To: Biomaven who wrote (905)	3/31/2000 3:14:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

Nothing that I say in the third paragraph is relevant to a current investment in NEXL. I have nothing against their current business plan. It's basically something that didn't fit with Baxter's concepts of what margins should look like, IMO. I have had modest interactions with the old Baxter unit for years. Good science, difficult in coming. We're talking about standardized procedures for the isolation of NEXL gets the bennies of all that hard work, and of that from CellPro. Richard Reeves is the guy to consult here. There is plenty of discussion of NEXL in the BVF thread. It derives from, IMO, the definitive "bait and switch" business plan for biotech, VimRx. Those days are gone.